Related Experiment Video
Updated: Mar 20, 2026

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
Update on advances in molecular PET in urological oncology
Kazuhiro Kitajima1, Shingo Yamamoto2, Kazuhito Fukushima3
1Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medical Center, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. kitajima@med.kobe-u.ac.jp.
Abstract:
Integrated positron emission tomography/computed tomography (PET/CT) with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of (18)F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. (18)F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

